WHO ICTRP trial
Randomized Phase II trial of Neoadjuvant weekly Nab-paclitaxel followed by FEC…
JPRN-UMIN000005388 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000005388 |
|---|---|
| Public title | Randomized Phase II trial of Neoadjuvant weekly Nab-paclitaxel followed by FEC compared with Docetaxel followed by FEC for early breast cancer |
| Scientific title | Randomized Phase II trial of Neoadjuvant weekly Nab-paclitaxel followed by FEC compared with Docetaxel followed by FEC for early breast cancer - ABI-007 Followed by FEC Neoadjuvant Chemotherapy for Breast Cancer (Randomized Phase II Trial) |
| Primary sponsor | Department of Breast Surgical Oncology, Showa University |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase II |
| Countries | Japan |
| Conditions | Breast Cancer |
| Interventions | After 4 course of Docetaxel and FEC, surgical resection is carried out. Docetaxel Docetaxel 75 mg/m2 is administered intravenously at day 1. One course is consisted by 3 weeks and repeated to 4 courses. FEC After administrated 4 courses of… |
| Registration date | Jan 6, 2011 |
| Target size | 150 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: